Related Party Transactions - Additional Information (Detail) - USD ($)				3 Months Ended		6 Months Ended
	May 17, 2024	Jan. 05, 2024	Dec. 18, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
Revenues				$ 9,477,000	$ 9,105,000	$ 21,161,000	$ 16,788,000
Total stock-based compensation expense				8,695,000	1,788,000	21,394,000	4,838,000
Research and development expense				29,822,000	15,730,000	60,011,000	29,348,000
Prepaid expenses				3,300,000		3,300,000		$ 1,695,000
License and Collaboration Agreement [Member]
Related Party Transaction [Line Items]
Revenues				7,782,000	$ 3,597,000	18,345,000	$ 3,631,000
Eyebiotech License Agreement [Member] | License and Collaboration Agreement [Member]
Related Party Transaction [Line Items]
Revenues	$ 500,000			500,000
Altasciences Company Inc [Member]
Related Party Transaction [Line Items]
Accounts payable				$ 600,000		$ 600,000		300,000
Other Liability, Related Party [Extensible Enumeration]				Accounts Payable, Current		Accounts Payable, Current
Research and development expense				$ 300,000		$ 900,000
Prepaid expenses				200,000		200,000		$ 500,000
Dr. John Landis [Member]
Related Party Transaction [Line Items]
Annual Compensation Payment			$ 600,000
Total stock-based compensation expense				200,000		400,000
Accounts payable				$ 100		$ 100
Other Liability, Related Party [Extensible Enumeration]				Accounts Payable, Current		Accounts Payable, Current
Dr. John Landis [Member] | Employee Stock Option
Related Party Transaction [Line Items]
Number of Options, Granted		20,000
Contractual life of option grants		1 year
Dr. John Landis [Member] | Restricted stock units [Member]
Related Party Transaction [Line Items]
Number of Stock Units, Granted		10,000
Dr. John Landis [Member] | Board Stock Option Award [Member]
Related Party Transaction [Line Items]
Number of Options, Granted		25,014